The urgency to treat optimally and to target: Avoiding long-term complications in type 2 diabetes with a focus on GLP-1 receptor agonists

Abstract

The wave of diabetes continues to increase in Canada and around the world. According to national data, 3.4 million Canadians were living with diabetes (type 1 and type 2 combined) in 2017–2018, compared to 1.3 million in 2000–2001. It is well-accepted that diabetes is a major cause of death and is the leading cause of renal failure, lower limb amputations and blindness in adults.